GO
Loading...

Vertex Pharmaceuticals Inc

More

  • Nov 19- Pharmaceutical investment firm Royalty Pharma said it would buy royalties on Vertex Pharmaceuticals Inc's cystic fibrosis treatments from Cystic Fibrosis Foundation for $3.3 billion in cash. Vertex's cystic fibrosis drug, Kalydeco, was approved by the U.S. Food and Drug Administration in January 2012. Vertex co-developed the drug with an affiliate...

  • Nov 19- Pharmaceutical investment firm Royalty Pharma said it would buy royalties on Vertex Pharmaceuticals Inc's cystic fibrosis treatments from Cystic Fibrosis Foundation for $3.3 billion in cash. Vertex's cystic fibrosis drug, Kalydeco, was approved by the U.S. Food and Drug Administration in January 2012. Vertex co-developed the drug with an affiliate...

  • What's boosting healthiest sector in S&P this year Monday, 27 Oct 2014 | 1:43 PM ET

    Health care has been on a tear in 2014, and there is still room for upside. Wall Street analysts are focusing on the following four trends.

  • Midday movers: GoPro, Tesla Motors, Yahoo & more Monday, 13 Oct 2014 | 1:03 PM ET

    Some of Monday's midday movers:

  • US STOCKS-Wall St little changed after selloff Monday, 13 Oct 2014 | 10:02 AM ET

    The benchmark S&P index slumped 3.1 percent last week to sit just above its support level, the 200- day moving average of around 1,905. The declines were sparked by a cut in the global growth forecast by the International Monetary Fund and disappointing economic data in Europe. Earnings season will pick up this week, with results expected from Dow components...

  • US STOCKS-Biotechs climb after two-day drop Wednesday, 24 Sep 2014 | 1:48 PM ET

    NEW YORK, Sept 24- Biotech stocks are moving higher on Wednesday, bouncing back from a two-day drop, helped by gains in Gilead Sciences after trial results for the company's HIV treatment.

  • US STOCKS-Biotech shares drop, Amarin plunges 20 pct Friday, 12 Sep 2014 | 12:49 PM ET

    NEW YORK, Sept 12- Biotech stocks were among the weakest sectors on Friday, falling as investors continued to take profit in the high-flying sector. Vertex Pharmaceuticals lost 1.2 percent to $93.10 while Amgen was off 0.9 percent to $137.64 and Regeneron Pharma lost 1 percent to $346.82.

  • Traders work on the floor of the New York Stock Exchange in New York.

    Stocks cut losses to close mixed on Thursday as geopolitical tensions lingered ahead of consumer data.

  • US STOCKS-Wall St falls, biotech stocks weaker Thursday, 11 Sep 2014 | 1:48 PM ET

    NEW YORK, Sept 11- U.S. stocks were lower on Thursday, with biotechnology shares among the weakest of the day as investors continued to take profits. Celgene Corp was the biggest decliner on the S&P 500, off 3 percent at $91.28, while Vertex Pharmaceuticals was down 2.3 percent at $92.60.

  • NEW YORK, Aug 13- U.S. stocks ended higher on Wednesday, with the Dow Jones industrial average returning to positive territory for the year, as surging biotech shares helped investors shrug off disappointing retail sales data.

  • Macy's Inc quarterly earnings missed analysts' estimates and the department store operator slashed its full-year same-store sales forecast, driving the stock down 5.5 percent to $56.47. Other major retailers, including Wal-Mart Stores Inc, are expected to report results on Thursday. Wal-Mart shares slipped 0.3 percent to $74.03.

  • Traders work on the floor of the New York Stock Exchange, Aug. 1, 2014, in New York.

    U.S. stocks closed higher for the third time in four days as a rally in tech, airlines and biotech firms helped lead gains.

  • US STOCKS-Wall Street rises, biotech shares lead rally Wednesday, 13 Aug 2014 | 2:56 PM ET

    NEW YORK, Aug 13- U.S. stocks rose on Wednesday, with the Dow returning to positive territory for the year as the market shrugged off weak earnings reports and a slump in retail shares. Biotech shares surged, with the Nasdaq biotech index climbing 2.1 percent on the back of stocks including InterMune Inc and Jazz Pharmaceuticals PLC.

  • Vertex to end sales of hepatitis C drug Incivek Wednesday, 13 Aug 2014 | 2:42 PM ET

    Aug 13- Vertex Pharmaceuticals Inc is stopping U.S. sales and distribution of its Incivek hepatitis C treatment, whose use has been largely supplanted by the new Sovaldi drug from Gilead Sciences Inc.. Incivek was approved in 2011 and quickly rose to annual sales of more than $1 billion.

  • Aug 1- Express Scripts Holding Co, the largest U.S. pharmacy benefit manager, on Friday said it will remove 25 products from its 2015 list of preferred drugs, including anemia treatments Epogen and Aranesp, both sold by Amgen Inc..

  • Pfizer's need for deal looms with earnings report Monday, 28 Jul 2014 | 7:12 AM ET

    Pfizer's vulnerability to cheap generics and its weak roster of experimental medicines will be on display Tuesday, when the company reports earnings.

  • NEW YORK, July 28- Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline.

  • This liver disease could rival hepatitis C Tuesday, 15 Jul 2014 | 8:06 AM ET

    The liver disease NASH is becoming more widespread, and the market for treatments may rival those for hepatitis C.

  • 10 stocks on Jim Cramer’s radar, right now Wednesday, 9 Jul 2014 | 6:07 PM ET
    Jim Cramer on Mad Money.

    Uncertain how to put money to work in a market that continues to flirt with all-time highs? Jim Cramer has a few ideas. Ten of them.

  • Check out which companies are making headlines after the bell Tuesday.